Test can identify patients in intensive care at risk of life-threatening infectionsJune 13, 2018
Patients in intensive care units are at significant risk of potentially life-threatening secondary infections, including from antibiotic-resistant bacteria such as MRSA and C. difficile. Now, a new test could identify those at greatest risk - and speed up the development of new therapies to help at-risk patients.
Infections in intensive care units (ICU) tend to be caused by organisms, such as multi-resistant gram-negative bacteria found in the gut, that are resistant to frontline antibiotics. Treating such infections means relying on broad spectrum antibiotics, which run the risk of breeding further drug-resistance, or antibiotics that have toxic side-effects.
Estimates of the proportion of patients in ICU who will develop a secondary infection range from one in three to one in two; around a half of these will be pneumonia. However, some people are more susceptible than others to such infections - evidence suggests that the key may lie in malfunction of the immune system.
In a study published in the journal Intensive Care Medicine, a team of researchers working across four sites in Edinburgh, Sunderland and London, has identified markers on three immune cells that correlate with an increased risk of secondary infection. The team was led by researchers at the Universities of Cambridge and Edinburgh and biotech company BD Bioscience.
"These markers help us create a 'risk profile' for an individual," explains Dr Andrew Conway Morris from the Department of Medicine at the University of Cambridge. "This tells us who is at greatest risk of developing a secondary infection.
"In the long term, this will help us target therapies at those most at risk, but it will be immediately useful in helping identify individuals to take part in clinical trials of new treatments."
Clinical trials for interventions to prevent secondary infections have met with mixed success, in part because it has been difficult to identify and recruit those patients who are most susceptible, say the researchers. Using this new test should help fine tune the selection of clinical trial participants and improve the trials' chances of success.
The markers identified are found on the surface of key immune cells: neutrophils (frontline immune cells that attack invading pathogens), T-cells (part of our adaptive immune system that seek and destroy previously-encountered pathogens), and monocytes (a type of white blood cell).
The researchers tested the correlation of the presence of these markers with susceptibility to a number of bacterial and fungal infections. An individual who tests positive for all three markers would be at two to three times greater risk of secondary infection compared with someone who tests negative for the markers.
The markers do not indicate which secondary infection an individual might get, but rather that they are more susceptible in general.
"As intensive care specialists, our priority is to prevent patients developing secondary infections and, if they do, to ensure they get the best treatment," says Professor Tim Walsh from the University of Edinburgh, senior author on the study.
The Immune Failure in Critical Therapy (INFECT) Study examined data from 138 individuals in ICUs and replicated findings from a pilot study in 2013.
A key part of enabling this study was to standardise how the research could be carried out across multiple sites, say the researchers. They used an imaging technique known as flow cytometry, which involves labelling components of the cells with fluorescent markers and then shining a laser on them such that they give off light at different wavelengths. This has previously been difficult to standardise, but the researchers successfully developed a protocol for use, ensuring they could recruit patients from the four study sites.
Conway Morris, A et al. Cell surface signatures of immune dysfunction risk stratify critically ill patients: INFECT Study. Intensive Care Medicine; June 2018; DOI: 10.1007/s00134-018-5247-0
Researcher Profile: Dr Andrew Conway Morris
Dr Andrew Conway Morris is an intensive care specialist at Addenbrooke's Hospital, part of Cambridge University Hospitals. It was the hospital's location on the Cambridge Biomedical Campus that attracted him back to the city where he had been born and raised.
"I moved to Cambridge in order to take advantage of the fantastic opportunities to work with some of the world's leading scientists, as well as develop collaborations with the growing biotech and pharmaceutical cluster centred around Addenbrooke's Hospital," he says.
Conway Morris undertook his undergraduate medical education in Glasgow before moving to Edinburgh to train in Anaesthesia and Intensive Care Medicine. His PhD in Edinburgh was on dysfunction of immune cells known as neutrophils in critically ill patients and looking at the development of new diagnostic tests for secondary pneumonia.
He is now a Wellcome-funded Senior Research Associate in the John Farman Intensive Care Unit at Addenbrooke's, where he is trying to find new ways to prevent and treat infections in hospitalised and critically-ill patients.
"I carry out my work using a combination of human cell models and animal models of pneumonia and aim to develop new therapies for infection that do not rely on antibiotics," he says. "I also have a clinical project evaluating a new molecular diagnostic test for pneumonia, which aims to deliver more rapid and accurate tests for infection."
Outside of work, it is his children that keep him occupied. "I have two boys who occupy most of my free time - both are football-mad - and I help run a local youth football team," he adds.
University of Cambridge
Related Antibiotics Articles:
Canadian researchers have generated both novel and existing antibiotic resistance mechanisms on experimental farmland, by exposing the soil to specific antibiotics.
UCSB biologists correct a flaw in the way bacterial susceptibility to these drugs is tested.
Fungi are a potential goldmine for the production of pharmaceuticals.
The growth of bacteria can be stimulated by antibiotics, scientists at the University of Exeter have discovered.
The ECDC's latest data on antimicrobial resistance and consumption shows that in 2015, antibiotic resistance continued to increase for most bacteria and antibiotics under surveillance.
Two widely prescribed antibiotics -- chloramphenicol and linezolid -- may fight bacteria in a different way from what scientists and doctors thought for years, University of Illinois at Chicago researchers have found.
News release describes efforts to address inappropriate antibiotic prescribing in emergency departments and urgent-care centers nationwide, which a JAMA study published this past May found rates as high as 50 percent for acute respiratory infections in US emergency departments.
Nine in 10 dairy farmers participating in a new survey from the Royal Association of British Dairy Farmers (RADBF) say that the farming industry must take a proactive lead in the battle against antibiotic resistance.
Antibiotics are advised in most guidelines on diverticulitis, which arises when one or more small pouches in the digestive tract become inflamed or infected.
'Antibiotics and Antibiotic Resistance' from CSHLPress examines the major classes of antibiotics, together with their modes of action and mechanisms of resistance.
Related Antibiotics Reading:
by Jason C. Gallagher (Author), Conan MacDougall (Author)
"This book focuses on key points of basic microbiology and antimicrobial pharmacotherapy and organizes them into a concise guide … must-have antimicrobial reference guide for all medical and pharmacy students." - Lindsay McDonnell, PharmD for Doody's Review Service
Antibiotics Simplified, Fourth Edition is a best-selling, succinct guide designed to bridge knowledge gained in basic sciences courses with clinical practice in infectious diseases. This practical text reviews basic microbiology and how to approach the pharmacotherapy of a patient with a presumed infection. It also... View Details
EMRA Antibiotic Guide, 17th Edition
by MD Brian J. Levine (Author)
Amoxicillin: Everything You Need To Know About The Popular Drug For Treating Bacterial Infections. (Uses, Dosage, Side Effects, etc)
by David V. Neff (Author)
Everything You Need To Know About The Popular Drug For Treating Bacterial Infections.
Amoxicillin is a well-known drug. The major reason for this is that it is effective for a wide range of conditions.
Amoxicillin is a drug from the penicillin circle of relatives that is used for the treatment of bacterial infections. The drug is generally commended for its absorption properties because it can be spread throughout the body’s tissues and fluids. As a result, taking amoxicillin can effectively treat a huge variety of conditions, which... View Details
Herbal Antibiotics, 2nd Edition: Natural Alternatives for Treating Drug-resistant Bacteria
by Stephen Harrod Buhner (Author)
With antibiotic-resistant infections on the rise, herbal remedies present a naturally effective alternative to standard antibiotics. Herbal expert Stephen Harrod Buhner explains the roots of antibiotic resistance, explores the value of herbal treatments, and provides in-depth profiles of 30 valuable plants, noting the proper dosages, potential side effects, and contraindications of each. View Details
Antibiotic Basics for Clinicians: The ABCs of Choosing the Right Antibacterial Agent
by Alan R. Hauser MD PhD (Author)
Easy-to-apply set of principles for selecting the right antibiotic
Antibiotic Basics for Clinicians, Second Edition, shows you how to apply your knowledge of pharmacology and microbiology in order to select the appropriate antibiotic. Rather than rely on rote memorization, you’ll learn the underlying rationale for treatment of common infectious diseases and pathogens. The text focuses on antibacterial agents, examining individual antibiotics and antibiotic classes as well as definitive and empiric therapies—providing a... View Details
Antibiotics Pocketcard Set 2016
by H. Hof (Author), R. Knueppel (Author)
Brand new View Details
Antibiotics: Challenges, Mechanisms, Opportunities
by Christopher Walsh (Author), Timothy Wencewicz (Author)
A chemocentric view of the molecular structures of antibiotics, their origins, actions, and major categories of resistance
Antibiotics: Challenges, Mechanisms, Opportunities focuses on antibiotics as small organic molecules, from both natural and synthetic sources. Understanding the chemical scaffold and functional group structures of the major classes of clinically useful antibiotics is critical to understanding how antibiotics interact selectively with bacterial targets.
This textbook details how classes of antibiotics interact with five known robust... View Details
Antibiotic Essentials 2017
by Burke A. Cunha (Author), Cheston Cunha (Author)
The new edition of this highly successful annual pocket guide presents clinicians with the most recent information in the field of antimicrobial therapy and infectious diseases. Written by recognised experts in infectious disease, this edition discusses serum and urinary spectrum summaries of antibiotics and clinically relevant pharmacokinetics. Completely new sections on Antibiotic Stewardship, IV-to-PO Switch Therapy, and differentiation of colonisation and infection, are also included. Unique features of this book include clinical synopses of common and uncommon infections worldwide,... View Details
MemoCharts Pharmacology: Antibiotics (Review chart)
by Howard Shen (Author)
An updated integrated mini review of antibiotics, illustrated with visually appealing tables and diagrams. A quick visual aide for the course study and board review View Details
Amoxicillin: Complete User Guide On The Perfect Medication for The Treatment Of Bacterial Infection.
by Dr Jane A. McCall (Author)
Complete User Guide On The Perfect Medication for The Treatment Of Bacterial Infection.
Amoxicillin, also spelled Amoxycillin, is an antibiotic which is use for the treatment of a number of bacterial infections. It's the first line treatment for middle ear infections. It is also used for strep throat, pneumonia, skin infections, and urinary tract infections amongst others. It's either you take it by mouth, or much less typically through injection.
Amoxicillin was discovered in 1958 and got into scientific... View Details